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8lung allografts transfected ex vivo with the immuno-
suppressive cytokine transforming growth factor–b 1
(TGF-b 1), complexed to liposomes, clearly showed
improved functional results when compared with non-
transfected allografts or allografts treated with TGF-b 1
antisense (unpublished data). These observations con-
firm the results of Qin, Ding, and Bromberg3 in the set-
ting of experimental heart transplantation.
W e have recently studied the feasibility, safety, andpattern of liposome-mediated gene transfer in a
rat lung transplant model.1,2 We demonstrated that gene
transfer to rat lungs can be achieved with minimal tox-
icity when grafts are transfected either before retrieval
(in vivo) or after organs had been harvested (ex vivo).
We also showed that gene therapy techniques can bring
functional benefits to lung grafts. We observed that rat
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In the current study, we compared the in vivo and ex
vivo approach in the setting of experimental lung trans-
plantation, using a liposomal vector delivered via the
vascular route. First, comparison was made using the
reporter gene chloramphenicol acetyltransferase (CAT).
Inasmuch as transgene expression per se does not assure
a functional effect, the observations gathered in the CAT
group were tested with the use of the functional gene
TGF-b 1. Thus comparison between the ex vivo and in
vivo approaches was also made on a functional basis.
Materials and methods
Plasmid expression vectors. The plasmid pCF1-CAT
(Genzyme Corporation, Framingham, Mass) consists of the
human cytomegalovirus immediate early gene promoter/
enhancer, a hybrid intron, the CAT cDNA, the bovine growth
hormone polyadenylation signal sequence, and a kanamycin
resistance gene, as previously described.4 The plasmids
pMP6ATGF-b 1 sense and antisense were supplied by one of us
(J. S. Bromberg, University of Michigan, Ann Arbor, Mich).
The pMP6ATGF-b 1 sense plasmid encodes for murine
TGF- b 1 driven by the cytomegalovirus promoter. The
pMP6ATGF- b 1 antisense plasmid contains the same
sequence as the pMP6ATGF-b 1 sense plasmid except that the
TGF-b 1 gene is inserted in an opposite direction in the plas-
mid, thus encoding no functional TGF-b 1 protein.
Liposomal vector. Lipid 67 (Genzyme Corporation) is an
amphiphile consisting of a hydrophobic lipid anchor (choles-
terol) linked to a spermine head group in a “T-shaped” con-
figuration. Lipid 67:dioleoylphosphatidylethanolamine
(DOPE), in a molar ratio of 1:2, was supplied as dried films
and prepared as previously described.3 Liposome:cDNA
complexes were prepared as described elsewhere.4
Animals. Inbred male Fischer and Brown-Norway rats
weighing 270 to 300 g (Charles River Laboratories,
Wilmington, Mass) were used in this study. Animals received
humane care in compliance with the “Principles of Lab-
oratory Animal Care” formulated by the National Society for
Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes of
Health (NIH Publication No. 85-23, revised 1985).
Rat lung transplantation. An orthotopic rat left lung
transplant model was developed with the use of a modifica-
tion5 of the “cuff” technique.6 In brief, donor lungs were
flushed through the main pulmonary artery with 20 mL of
normal saline solution at a pressure of 10°C and 20 cm H2O.
The heart-lung block was excised with the lungs inflated at
end-tidal volume and the left pulmonary vein was cannulated
with a silicone catheter inserted through the left atrial
appendage. In the ex vivo setting, lipid 67:DOPE:cDNA was
diluted in 5 mL of normal saline solution and infused retro-
gradely over 7 to 10 minutes at a pressure of 20 cm H2O. In
the in vivo setting, grafts were infused with normal saline
solution alone. Subsequently, the left lung was dissected and
14-gauge cuffs were inserted into the left pulmonary artery
and vein. Grafts were implanted by means of the “cuff” tech-
nique for vascular anastomoses and suture technique for
bronchial anastomoses (Prolene [Ethicon, Inc, Somerville,
NJ] or nylon 8-0 or 9-0).
Experimental design. The study was divided into 2 main
groups: CAT, which is a reporter gene, and TGF-b 1, which is
a functional gene. Each group was subdivided into ex vivo
and in vivo settings.
CAT group. Fischer rats underwent isogeneic left lung
transplantation and were divided into 6 groups (n = 4 per
group). The preservation temperature was 10°C in all groups.
Recipients were put to death on postoperative day 2 for mea-
surement of CAT activity by means of the CAT assay as
described elsewhere.7 Relative densitometry of the chro-
matographs of the CAT assay was performed with the use of
Scion Image, an adaptation of the National Institutes of
Health Image program for Windows 95.
EX VIVO SETTING. In group I, grafts were infused ex vivo
with 660 m g of CAT cDNA complexed to liposomes and then
transplanted immediately, with a resultant exposure time of
approximately 1.5 hours. Group II was similar to group I
except that the exposure time was 10 hours at 10°C. In group
III, grafts were infused ex vivo with naked CAT cDNA alone,
not complexed to liposomes, and then transplanted after an
exposure time of approximately 1.5 hours at 10°C.
IN VIVO SETTING. In group IV, donors received an intra-
venous injection of 1320 m g of CAT cDNA complexed to
liposomes via a cutdown approach to the left external jugular
vein. After an exposure time of 1.5 hours in the animal, left
lungs were harvested, preserved for an additional 1.5 hours at
10°C, and then implanted. Group V animals were similar to
group IV except that the exposure time was 10 hours in the
animal and the preservation time was an additional 10 hours
at 10°C. In group VI, donors were injected with 1320 m g of
naked CAT cDNA by means of a similar approach. The expo-
sure time in the animal was 1.5 hours, and the preservation
time was an additional 1.5 hours at 10°C before implantation.
TGF-b 1 group. Brown-Norway rats served as donors and
Fischer rats as recipients. There were 4 groups.
EX VIVO SETTING. In group I (n = 7), Brown-Norway left
lungs were transfected ex vivo with 660 m g of TGF-b 1 anti-
sense cDNA complexed to liposomes, preserved for 3 hours
at 10°C, and then transplanted into Fischer rats. In group II (n
= 8), Brown-Norway left lungs were treated in the same way,
but were transfected with TGF-b 1 sense cDNA complexed to
liposomes. In group III (n = 5), Brown-Norway grafts were
transfected with naked TGF-b 1 sense cDNA.
IN VIVO SETTING. In group IV (n = 7), Brown-Norway rats
received an intravenous injection of 1320 m g of TGF-b 1
sense cDNA complexed to liposomes via the left external
jugular vein. After 3 hours of exposure in the animals, the left
lungs were harvested, preserved for an additional 3 hours at
10°C, and then transplanted.
No immunosuppressive drugs were used in any of the
groups. All recipients were put to death on postoperative day 5,
based on previous studies (unpublished data). Arterial oxy-
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genation was measured after crossclamping of the right hilum,
which resulted in the perfusion and ventilation of the trans-
planted left lung allograft only. An arterial blood sample was
obtained from the aorta after left lung allograft ventilation for
5 minutes (100 strokes/min; inspired oxygen fraction = 1.0;
tidal volume = 1.5 mL). After formalin fixation of the trans-
planted lungs, standard hematoxylin-eosin staining was per-
formed. Histologic rejection was scored by a lung transplant
pathologist blinded to the protocol according to the 1995 revi-
sion of the working formulation for the classification of pul-
monary allograft rejection.8 Vascular and airway rejection
scores were graded on a scale of 0 (no rejection) to 4 (complete
graft destruction).
Statistical analysis. Data were expressed as mean ± stan-
dard deviation. Data were compared by 1-way or 2-way
analysis of variance and Fisher’s post hoc multiple compari-
son technique as applicable, using the software Systat for
Windows version 7 (Systat, Inc, Evanston, Ill, 1996).
Results
There were no operative deaths in any of the groups.
CAT group. CAT activity was superior in the ex vivo
group, as demonstrated by the CAT assay chromato-
grams. Increasing the exposure time from 1.5 to 10
hours did not improve transfection rate (Fig l, A, B, and
C). Transfection with naked CAT cDNA resulted in
transgene expression when infused by either the in vivo
or ex vivo approaches.
TGF-b 1 group. Grossly, allografts treated ex vivo
with liposome:TGF-b 1 sense cDNA were similar to
native right lungs (Fig 3, C). Allografts treated in vivo
showed a similar gross appearance. Conversely, lungs
treated ex vivo with liposome:TGF-b 1 antisense cDNA
or TGF-b 1 sense cDNA not complexed to liposomes
showed diffuse hemorrhage and pulmonary edema (Fig
3, A and B).
Arterial oxygen tension was better in the ex vivo lipo-
some:TGF-b 1 sense group than in the in vivo lipo-
some:TGF-b 1 sense group and ex vivo liposome:TGF-b 1
antisense group. Allograft function was superior in both
groups treated ex vivo and in vivo with liposome:TGF-b 1
sense compared with those treated with TGF-b 1 sense
cDNA not complexed to liposomes (Fig 4).
Vascular rejection scores were 2.0 ± 0.53 (95% CI
1.55-2.44) versus 2.35 ± 0.47 (95% CI 1.91-2.79) ver-
Fig 1. Lung CAT activity was analyzed by means of thin-layer chromatography. Each column corresponds to 1
animal. The bottom row represents non-acetylated chloramphenicol. The middle and top rows represent
monoacetylated and diacetylated chloramphenicol, respectively. Overall, CAT activity was higher in the ex vivo
(B) than in the in vivo setting (A); P = .02 (2-way analysis of variance; Fischer’s least significant difference test).
Interestingly, CAT activity was higher in grafts exposed for 1.5 hours than in grafts exposed for 10 hours, but the
difference did not reach statistical significance: P = .4 for the in vivo setting and P = .1 for the ex vivo setting. C,
Relative densitometry of the chromatographs seen in A and B. Error bars represent standard deviations.
A B
C
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sus 2.83 ± 0.68 (95% CI 2.11-3.55) versus 2.6 ± 0.22
(95% CI 2.32-2.87) for ex vivo liposome:TGF-b 1
sense, in vivo liposome-TGF-b 1 sense, ex vivo lipo-
some:TGF-b 1 antisense, and ex vivo TGF-b 1 sense
cDNA alone, respectively.
Airway rejection scores were l.27 ± 0.66 (95% CI
0.76-1.79) versus 1.57 ± 0.34 (95% CI 1.25-1.89) ver-
sus 2.33 ± 0.81 (95% CI 1.47-3.19) versus 2.2 ± 0.27
(95% CI 1.86-2.54) for ex vivo liposome:TGF-b 1
sense, in vivo liposome:TGF-b 1 sense, ex vivo lipo-
some:TGF-b 1 antisense, and ex vivo TGF-b 1 sense
cDNA alone, respectively.
There was no statistically significant difference
between the ex vivo and in vivo liposome:TGF-b 1
sense groups (P = .14 and .33 for vascular and airway
rejection scores, respectively; 1-way analysis of vari-
ance, Fisher’s least significant difference test).
There was a statistically significant difference
between the ex vivo liposome:TGF-b 1 sense and ex
vivo liposome:TGF-b 1 antisense groups (P = .009 and
.002 for vascular and airway rejection scores, respec-
tively; 1-way analysis of variance, Fisher’s least signif-
icant difference test).
There was no statistically significant difference in
vascular rejection scores between the in vivo lipo-
some:TGF- b 1 sense group and the ex vivo
liposome:TGF-b 1 antisense group (P = .19; 1-way
analysis of variance, Fisher’s least significant difference
test). There was, however, a statistically significant dif-
ference between these 2 groups when airway rejection
scores were examined (P = .03; 1-way analysis of vari-
ance, Fisher’s least significant difference test). We did
not observe any functional benefits in grafts treated ex
vivo with TGF-b 1 sense cDNA alone, as measured by
either allograft arterial oxygenation or rejection scores.
Discussion
In organ transplantation, the donated organ can be
transfected either in vivo or ex vivo, that is, before or
after retrieval. In lung transplantation, gene transfer can
be achieved by delivering the vector:cDNA complexes
via the pulmonary vasculature or the airways.
Fig 2. CAT activity in grafts treated with cDNA only versus cDNA complexed to liposomes. Each column cor-
responds to 1 animal. A, CAT activity was lower in lung isografts treated either in vivo or ex vivo with CAT
cDNA alone in comparison with lung isografts treated in vivo or ex vivo with CAT cDNA complexed to lipo-
somes. B, Relative densitometry of the chromatographs seen in A. Error bars represent standard deviations.
A
B
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We have recently described our results delivering the
reporter gene CAT complexed to liposomes via the vas-
cular route.1,2 When the liposome:cDNA complexes
were delivered in vivo to the donor via an injection into
the external jugular vein, transgene expression was
strong in both hearts and lungs, minimal in livers, and
not detectable in kidneys.1 Conversely, when lung
grafts were infused ex vivo with liposome:cDNA com-
plexes, transgene expression was minimal in hearts and
not detected in livers and kidneys. The minimal trans-
fection present in hearts could be eliminated by flush-
ing the lung grafts with normal saline solution before
implantation. Further, the duration of transgene expres-
sion was longer with the ex vivo approach than with the
in vivo approach.1,2,9
In this current study, we compared the efficacy of
both approaches using the vascular route. Our results
demonstrate that the ex vivo strategy is more effective.
In the CAT group, we observed superior transfection
rates in the ex vivo liposome:CAT cDNA group than in
the other groups. Importantly, this observation was
affirmed with the use of TGF-b 1, whereby improve-
ments in both graft function and histologic characteris-
tics were observed after the ex vivo treatment of lung
allografts with TGF-b 1 sense cDNA complexed to
liposomes. Arterial oxygen tension 5 days after trans-
plantation was superior in the ex vivo liposome:TGF-
b 1 sense group in comparison with the in vivo group or
the ex vivo liposome:TGF-b 1 antisense group.
There was considerable variability in arterial oxy-
genation measurements in both the ex vivo and in vivo
liposome:TGFb 1 sense groups. We also noticed vari-
ability of CAT activity within the same CAT groups,
reflecting variable levels of gene transfer and produc-
tion of the protein-of-interest in lungs treated under the
same conditions. This could potentially explain the
variable results observed in the TGF-b 1 group regard-
ing arterial oxygen tension.
We believe that the amount of infused cDNA is sim-
ilar between the in vivo and ex vivo groups for the fol-
lowing reasons. In the in vivo approach, most of the
liposome:cDNA complexes injected intrajugularly
remain in the heart and lungs, with minimal systemic
transfection.1 Both the right and left lungs are affected
when this approach is used. In the ex vivo approach,
the entire liposome:cDNA complex enters the pul-
monary vasculature, with resultant selective transfec-
tion of left lungs. Inasmuch as both lungs are transfect-
ed using the in vivo approach and only left lungs are
transfected using the ex vivo approach, we doubled the
dose of liposome:cDNA complexes for use in the in
vivo approach. It should be stated, however, that
increasing the amount of liposome:cDNA complexes
delivered intravenously may improve the results in the
in vivo setting. If this is true, it further strengthens the
superiority of the ex vivo strategy in that lower
amounts of liposome:cDNA complexes are used with
lower systemic transfection rates.
A B C
Fig 3. A, Gross pathology of a Brown-Norway allograft on posttransplantation day 5 treated ex vivo with lipo-
some:TGF-b 1 antisense cDNA. Lungs showed extensive hemorrhage and edema, which was also observed in (B)
allografts treated with naked TGF-b 1 sense cDNA. C, Gross pathology of a Brown-Norway allograft on post-
transplantation day 5, treated ex vivo with liposome:TGF-b 1 sense cDNA. Allografts showed no edema or hem-
orrhage and were well ventilated.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 1
Boasquevisque et al   13
Histologic rejection scores in the ex vivo lipo-
some:TGF-b 1 sense group did not differ significantly
from those in the in vivo group, making it difficult to
explain the better allograft function in the former. It
should be stated, however, that histologic examination
is a crude method to analyze the rejection process.
The results obtained in the ex vivo setting also
demonstrate that ischemia and low temperatures do not
interfere with the cellular uptake of cationic
lipid:cDNA complexes, although they do delay trans-
gene expression. We have previously demonstrated2
that transgene expression is not present during cold
storage, even after prolonged incubation times of 12
hours at 10°C, a temperature at which lungs are thought
to still maintain aerobic metabolism.10
Transgene expression does occur in lung grafts when
naked cDNA is administered without being complexed
to liposomes. The amount of transgene expression,
however, is at lower levels compared with cDNA com-
plexed to liposomes, as was observed in the CAT
group. However, the levels obtained are not high
enough to produce a functional effect, as we demon-
strated using the TGF-b 1 gene. Arterial oxygen tension
and histologic rejection scores were similar to the ones
observed in the control group transfected with lipo-
some:TGF-b 1 antisense cDNA.
Finally, one should consider the several factors that
may affect liposome-mediated gene transfer efficiency,
such as (1) the neutral lipid used, (2) the structure of the
cationic lipid moiety, (3) the size of liposomal particles
(large multilamellar or small unilamellar vesicles), and
(4) host tissue factors.11 As we better understand the
regulatory processes involved in DNA expression, we
will be able to improve vector technology and enhance
gene therapy strategies.
In summary, this study demonstrates that (1) with the
use of current liposome technology, the ex vivo
approach is superior to the in vivo approach in experi-
mental lung transplantation when the liposome:cDNA
complexes are delivered via the vascular route and (2)
infusion via the pulmonary vasculature of naked cDNA
that is not complexed to liposomes produces transgene
expression, although not at levels sufficient to produce
functional effects in this model.
We acknowledge the assistance of Richard B. Schuessler,
PhD, in the statistical analyses and Kathy Grapperhaus in the
experimental assays.
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Discussion
Dr Hikaru Matsuda (Osaka, Japan). I congratulate you
for your excellent results with a fine gene transfection model.
In the group at Osaka University Medical School, we have
been conducting gene transfection experiments using the
HVJ liposome method. The target organs have been the liver,
the heart, the kidneys, and recently the lungs. The efficacy
has been very high compared with the conventional method
including adenovirus vector and simple liposome method.
Recently, using the HVJ method, my colleague, Dr Takeda,
has shown an interesting result of producing the histologic
changes similar to obliterative bronchiolitis seen in chronic
lung transplant rejection using intratracheal injection of
endothelin-1 gene. I agree that transplantation can provide a
unique opportunity for gene transfer during harvest and stor-
age in the ex vivo state to understand the mechanism of rejec-
tion, as well as to reduce the ischemic injury. How do you
rate the efficiency of the liposome method in comparison
with the other methods you have evaluated? Have you tried
the intratracheal injection method?
Dr Boasquevisque. Thank you very much for your com-
ments. Indeed, we are conducting some studies in which we
are administering a liposomal vector complexed to TGF-b 1
cDNA through the airways. We are getting encouraging results.
Regarding the use of the HVJ-liposome vector, I think you
are right. The ideal vector is not established yet, and much work
has to be done in this field. It is worthwhile to try this vector. 
Dr Thomas M. Egan (Chapel Hill, NC). I have 2 ques-
tions. Your outcome was gas exchange. Did you clamp the
right hilum or did you just ventilate the left lung?
Dr Boasquevisque. During the assessment the right hilum
was always clamped for 5 minutes
Dr Egan. Did you look at a product of gene expression and
try to correlate that with rejection scores? 
Dr Boasquevisque. We did try to measure the levels of
TGF-b 1 using 2 different methods, luciferase and enzyme-
linked immunosorbent assay, but we did not succeed. We
could not even show a difference between transfected and
nontransfected normal lungs. That is why we used the CAT
gene, with which it is easier to detect the protein expression.
Dr Walter Weder (Zurich, Switzerland). How much is
known concerning the temperature dependence of transfec-
tion? Is there any transfection at 4°C and is 15°C better than
10°C? Is there a difference in the temperature dependency
between different vectors?
Dr Boasquevisque. We have conducted a series of experi-
ments in which we checked the effect of temperature on
transgene expression. First, we used the reporter gene CAT,
and it seemed to have a better transfection rate at 10°C.
However, when we used the functional gene TGF-b 1, we did
not detect any difference with regard to a functional benefit to
the allograft, transfecting the lung at either 4°C or 10°C.
With regard to the adenoviral vector, we have previously
demonstrated that low temperatures such as 4°C or 10°C do
not interfere with adenovirus-mediated gene transfer.
Mr Peter Goldstraw (London, England). I have a little
difficulty with the equivalence of your dosages. You gave 660
m g into 1 lung and you doubled the dose when you put it into
the whole body. Is that not just a dose effect?
Dr Boasquevisque. When we treated the donor in vivo, we
injected the liposome:cDNA complexes through the jugular
vein, so that the entire liposomal-DNA load would be direct-
ed to the heart-lung block. The problem is that part of the
complex is trapped in the heart. With current liposome tech-
nology, there are anatomic barriers to overcome until the
liposome-DNA load reaches the target, which is the lung in
our study, when we use the in vivo approach. This does not
occur in the ex vivo approach, in which the liposome:DNA
complexes are delivered directly to the pulmonary vascula-
ture. As a result, a much smaller amount is needed to trans-
fect the lungs ex vivo. We probably could get the same results
in the ex vivo approach using a smaller amount of lipo-
some:DNA complex than we used in this current study,
because we did not clamp the pulmonary artery while infus-
ing the liposome:DNA complexes via the pulmonary vein.
This fact per se strengthens the superiority of the ex vivo
approach over the in vivo approach. Besides the advantage in
terms of dosage, target specificity can be achieved with the ex
vivo approach. Because of these facts, it seems to me that
with current liposome technology, the ex vivo approach is
more efficient than the in vivo approach when the vascular
route is used.
Dr Larry R. Kaiser (Philadelphia, Pa). Do you have any
indication of how long transgene expression persists with the
ex vivo versus the in vivo approach?
Dr Boasquevisque. Yes, we have published a study in which
we demonstrated that, in the ex vivo approach, transgene
expression is very strong 28 days after transfection, whereas in
the in vivo approach, transgene expression was almost zero at
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1 day. On checking further, we showed that the transgene is
expressed for 45 days when the lung is transfected ex vivo. 
Dr Kaiser. In these models that you observed, do you see
transgene expression in other organs whether you have trans-
duced them ex vivo or in vivo? Are you seeing expression in
the liver, for instance? 
Dr Boasquevisque. When the lungs are transfected in vivo,
through the intrajugular route, a very strong transgene expres-
sion will be seen in the heart, equivalent to what we observe
in the lungs. There is minimal expression in the liver, and we
could not detect expression in the kidneys. Using the ex vivo
approach, we detect minimal transgene expression in the
heart, which can be eliminated by giving an additional flush
to the lung graft immediately before implantation.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Follow-
ing along the lines of Mr Goldstraw’s comment, I think we
need to develop many ways of optimizing transfection to the
donor organ. You have been looking at the transvascular
route. It needs to be emphasized that your findings as to the
efficacy of ex vivo transfection reflect the route that you have
chosen. The ex vivo route gets around the problem of dilution
and the dose effect that was mentioned, as well as the effect
of time of exposure to the pulmonary endothelium. If you are
going to use the pulmonary endothelial route, the vascular
route, you are going to need directed gene therapy, either viral
or liposomes that are targeted. Your findings may not gener-
alize to ex vivo being better by the transtracheal route. Have
you done those experiments with TGF-b by the transtracheal
route? 
Dr Boasquevisque. With current liposome technology and
the vascular route, the ex vivo approach is more efficacious.
In the current study, we used the vascular route. However, the
airway route is being used in another study in our laboratory,
and we are getting similar results.
The vascular route is very attractive in the setting of lung
transplantation, chiefly if we consider that the endothelium is
the first structure of the graft to contact the host inflammatory
cells.
Dr Keshavjee. One other small technical question: Do you
clamp the vessels to increase the contact time and/or pressure
in the vessels? 
Dr Boasquevisque. We did not clamp the vessels. The
liposome:DNA complexes were infused under a pressure of
20 cm H2O through the pulmonary vein over a period of 7 to
10 minutes. We did not clamp the pulmonary artery because
we were afraid of injuring the endothelium due to the resul-
tant high pressure. 
Dr Keshavjee. I think that little bit of injury may work to
your advantage in terms of increasing liposomal uptake in the
endothelium.
